Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=70 A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Anemia
Primary: Change From Baseline in Mean Hb Concentration at Week 20 — 8.820; 1.440 Grams per deciliter (gm/dL) — p=<0.0001
N/A N=312 A Study of Bimatoprost 0.01% in the Clinical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale — 7; 36; 10; 50 Patients
N/A N=21 A Two-Phase Clinical Study of the Minerva AURORA Ablation System
Menorrhagia Due to Benign Causes
Primary: Reduction in Menstrual Blood Loss to Normal Levels at 12-months — 20 participants
N/A N=1,074 More Options Available With a Quadripolar LV Lead pRovidE In-clinic Solutions to CRT Challenges
Postoperative Cardiac Complication · Heart Failure · Left Ventricular Cardiac Dysfunction
Primary: Lead Performance — 83; 74.4 % of patients with freedom from event
Phase 2 N=32 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Invasive Pulmonary Aspergillosis · Lymphoblastic Leukaemia · Myeloblastic Leukaemia
Primary: Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability — 0 participants
Phase 2 N=395 Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
Hepatitis C Virus
Primary: Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR) — 54.4; 54.1; 13.9 percentage of participants
Phase 2 N=48 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
Hepatitis C Infection
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12 — 41.7; 83.3; 75; 8.3 percentage of participants
Phase 4 N=89 Effect of Nebulized Bronchodilators on Heart Rate
COPD · Sepsis · Shock
Primary: Heart Rate in Beats Per Minute — -0.16; 1.40 bpm — p=0.01
N/A N=38 Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Epilepsy · Psychiatric or Mood Diseases or Conditions
Primary: Levels of Folate Receptor Autoantibodies — 35.33; 35.21; 44.3; 41.81 ug/mL
Phase 3 N=768 Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Multiple Myeloma
Primary: Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination…
Phase 3 N=243 Dysport® Adult Upper Limb Spasticity
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
Phase 2 N=211 Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12) — 96.4; 85.7; 95.0; 100.0 Percentage of participants
Phase 1 N=60 Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
Hyperlipidemia
Primary: Number of Participants With Adverse Events — 7; 2; 5; 4 participants
Phase 2 N=117 Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
Squamous Cell Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) — 14.5 Percentage of Participants